 NEW YORK, Dec. 1, 2021 PRNewswire -- Mind Medicine MindMed Inc. NASDAQ: MNMD, NEO: MMED, DE: MMQ the Company, a leading biotech company developing psychedelic-inspired therapies, today announced that MindMeds Chief Executive Officer, Robert Barrow, will participate in a panel and Companys management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021. 